[go: up one dir, main page]

MX2017007970A - Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro. - Google Patents

Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro.

Info

Publication number
MX2017007970A
MX2017007970A MX2017007970A MX2017007970A MX2017007970A MX 2017007970 A MX2017007970 A MX 2017007970A MX 2017007970 A MX2017007970 A MX 2017007970A MX 2017007970 A MX2017007970 A MX 2017007970A MX 2017007970 A MX2017007970 A MX 2017007970A
Authority
MX
Mexico
Prior art keywords
brain
precursor
application
neurotrophic factor
derived neurotrophic
Prior art date
Application number
MX2017007970A
Other languages
English (en)
Inventor
Li Changqi
Wang Huamao
Dai Ruping
Cai Xiumei
Zhou Xinfu
Original Assignee
Shanghai Yile Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yile Biotechnology Co Ltd filed Critical Shanghai Yile Biotechnology Co Ltd
Publication of MX2017007970A publication Critical patent/MX2017007970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se divulga el uso de una molécula de enlace que enlaza específicamente a un precursor del factor neurotrófico derivado del cerebro (proBDNF) . La molécula de enlace a proBDNF, especialmente un anticuerpo monoclonal contra proBDNF, puede utilizarse para prevenir, mitigar o tratar enfermedades autoinmunes.
MX2017007970A 2014-12-19 2015-12-18 Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro. MX2017007970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410811678.8A CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
PCT/CN2015/097820 WO2016095839A1 (zh) 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Publications (1)

Publication Number Publication Date
MX2017007970A true MX2017007970A (es) 2018-04-13

Family

ID=56125955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007970A MX2017007970A (es) 2014-12-19 2015-12-18 Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro.

Country Status (11)

Country Link
US (2) US10556947B2 (es)
EP (1) EP3235507B1 (es)
JP (2) JP6758317B2 (es)
KR (1) KR20170104487A (es)
CN (2) CN105770889B (es)
AU (1) AU2015366363B2 (es)
CA (1) CA2971823A1 (es)
ES (1) ES2826523T3 (es)
MX (1) MX2017007970A (es)
SG (1) SG11201705004VA (es)
WO (1) WO2016095839A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
MX2020002351A (es) * 2017-08-28 2021-02-26 Shanghai Yile Biotechnology Co Ltd Polipeptido y anticuerpo unido al polipeptido.
US20220064274A1 (en) * 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
CN114660296B (zh) * 2020-12-23 2025-07-15 深圳市安群生物工程有限公司 一种脑源性神经营养因子测定试剂盒及其应用和脑源性神经营养因子特异性抗体
CN112574305B (zh) * 2020-12-30 2022-04-22 深圳清华大学研究院 针对前体脑源性神经营养因子的抗体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
CN118085080A (zh) * 2024-02-28 2024-05-28 湖南永和阳光生物科技股份有限公司 一种检测神经退行性疾病的单克隆抗体组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009150B1 (en) * 2009-02-12 2019-11-13 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2481754B1 (en) 2009-09-22 2014-06-18 Shanghai Yijie Biotechnology Co., Ltd Specific binding proteins and uses thereof
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Also Published As

Publication number Publication date
AU2015366363A1 (en) 2017-07-13
CN107206078A (zh) 2017-09-26
US10556947B2 (en) 2020-02-11
JP2020200340A (ja) 2020-12-17
AU2015366363B2 (en) 2021-09-02
CN105770889B (zh) 2021-06-01
US20210017264A1 (en) 2021-01-21
EP3235507B1 (en) 2020-09-30
CN105770889A (zh) 2016-07-20
EP3235507A1 (en) 2017-10-25
JP6758317B2 (ja) 2020-09-23
KR20170104487A (ko) 2017-09-15
WO2016095839A1 (zh) 2016-06-23
US20170362313A1 (en) 2017-12-21
JP2018502905A (ja) 2018-02-01
CA2971823A1 (en) 2016-06-23
ES2826523T3 (es) 2021-05-18
HK1244712A1 (en) 2018-08-17
SG11201705004VA (en) 2017-07-28
EP3235507A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
ZA202307128B (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
MX2017007970A (es) Uso de una molécula de unión que se une específicamente al precursor del factor neurotrófico derivado del cerebro.
PH12019502283A1 (en) Anti-lag3 antibodies
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
GEP20217331B (en) Anti-tigit antibodies
PH12016501763A1 (en) Multispecific antibodies
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
EP4272738A3 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
AU2016263598A8 (en) Methods and kits for treating depression
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EP3137504A4 (en) Antibody binding to fcrn for treating autoimmune diseases
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EP3197437A4 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
MX2018007221A (es) Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa).
TWD171533S (zh) 遙控器
MX2017006488A (es) Sistema de encuadernacion doble.
UA103980C2 (ru) Способ консервативного лечения апоплексии яичника с минимальным гемоперитонеумом
HK40014182A (en) Methods of treating obesity with anti-angptl8 antibodies